Biogen
Tracked across 25 events · 293 articles · First seen Feb 19, 2026 · Last active Aug 18, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Tech
Impact: Biogen announced compelling topline results from its Phase 2 CELIA study for diranersen, showing robust biomarker impact and cognitive benefit in early Alzheimer's disease, despite not meeting the primary endpoint for dose response. This positive data gives Biogen confidence to advance diranersen to registrational development.
May 14, 2026 · 7 articles
Business
Impact: Biogen is acquiring RayThera Inc. to expand its immunology pipeline and strengthen its long-term strategy in immune-mediated diseases. This acquisition adds early-stage assets and is Biogen's second major acquisition this year.
Jun 17, 2026 · 10 articles
Regulatory
Impact: Biogen is under investigation by Pomerantz LLP for alleged securities fraud after its stock price fell following the announcement of Phase 2 CELIA study results that missed its primary endpoint.
May 21, 2026 · 21 articles
Tech
Impact: Biogen's diranersen showed promising Phase II results, slowing cognitive decline by 26% in early Alzheimer's. The company plans a Phase III trial, positioning it as a leader in tau-targeting therapies.
Jul 14, 2026 · 22 articles
Tech
Impact: Biogen produces lecanemab (Leqembi), an anti-amyloid drug whose efficacy was challenged by the Cochrane review, which could negatively affect its market performance.
Apr 16, 2026 · 6 articles
Domestic
The Republic of Ireland — Health Service Executive (HSE) Drugs Group recommended against reimbursing the drug Skyclarys (omaveloxolone) for the treatment of Friedreich's Ataxia, a rare progressive neuromuscular condition affecting about 200 people in Republic…
Impact: Manufacturer of Skyclarys; the HSE recommendation against funding could limit market access in Republic of Ireland, though the drug is approved in the EU.
Aug 14, 2026 · 8 articles
Tech
Researchers from the University of Miami, led by Michael Bell and Joanne Wuu, analyzed data from the NIH-funded Pre-fALS study to identify a panel of 19 blood proteins that can predict the onset of ALS…
Impact: Biogen's drug Tofersen is being evaluated in the ATLAS trial for pre-symptomatic ALS, potentially expanding its market.
Jul 27, 2026 · 12 articles
Business
Impact: Biogen is a partner in Leqembi commercialization; the sales results contribute to its Q2 2026 report.
Jul 29, 2026 · 6 articles
Business
Impact: Biogen had an executive, Bharti Rai, recognized with an Ignite Leadership Award for driving enterprise-wide AI transformations within the company.
Jun 25, 2026 · 8 articles
Business
Impact: Biogen collaborates with Eisai on Leqembi development and commercialization, benefiting from the India launch through co-commercialization.
Aug 03, 2026 · 6 articles
Tech
Cumulus Neuroscience announced the publication of final results from its CNS-102 study in Scientific Reports, demonstrating that its at-home NeuLogiq Platform is feasible, well tolerated, and highly usable for multimodal cognitive assessment in people living…
Impact: Biogen is a member of the pre-competitive consortium that collaborated on the CNS-102 study. The results may inform its ALS and FTD clinical trial designs.
Aug 18, 2026 · 6 articles
Business
Impact: Biogen is a joint development and commercialization partner for Lecanemab, participating in clinical studies. While not the primary focus of this sales forecast, it benefits from the drug's success.
May 25, 2026 · 7 articles
Business
Impact: Biogen was an early partner of Scribe, providing initial backing. While not directly involved in the IPO, the partnership highlights Scribe's early validation.
Jul 06, 2026 · 25 articles
Business
Impact: Biogen is a commercial partner for Zurzuvae, sharing revenue with Supernus; the merger may affect this partnership.
Aug 03, 2026 · 6 articles
Tech
Impact: Biogen is a funding partner for the project, supporting the research into Alzheimer s disease biomarkers.
Feb 19, 2026 · 6 articles
Business
Impact: Biogen is mentioned as McDonnell's former employer; no direct impact on Biogen.
Jul 08, 2026 · 6 articles
Tech
A nationwide Swedish observational study from Karolinska Institute, published in the European Heart Journal, found that patients with both atrial fibrillation and Alzheimer's disease who were treated with newer oral anticoagulants (NOACs) experienced a significantly…
Impact: Greta Duréel has consulted for Biogen, but no direct impact from this study.
Aug 12, 2026 · 6 articles
Business
Impact: Biogen entered into a joint development and commercialization agreement for lecanemab with Eisai in 2014 and is involved in the AHEAD 3-45 clinical study.
May 15, 2026 · 6 articles
Business
Impact: Dr. Michelle Mellion previously held positions at Biogen, contributing to programs spanning remyelination.
May 12, 2026 · 6 articles
Business
Impact: Biogen>>> partly financed a phospho-tau vaccine program advanced by Declion Holdings LLC>>>.
May 19, 2026 · 6 articles
Business
Impact: Biogen, in collaboration with Eisai, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
Business
Impact: Patrick Vink held senior executive roles at Biogen.
Jul 08, 2026 · 6 articles
Business
Impact: Mentioned as comparison for premium paid in acquisitions.
Jul 06, 2026 · 34 articles
65
Biogen evaluatingALS blood biomarker panel...
ERGEN INTELLIGENCE
Track Biogen live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard